Evidence map›Paper›PMID 40216992›Full record

ArticleJournal of human genetics2025

Regulation of MCCC1 expression by a Parkinson's disease-associated intronic variant: implications for pathogenesis.

Shunsaku Sogabe, Hiroko Nakano, Yusuke Ogasahara, Pei-Chieng Cha, Yuko Ando, Mariko Taniguchi-Ikeda, Ryusaku Matsumoto, Motoi Kanagawa, Kazuhiro Kobayashi, Shigeo Murayama and 3 more

Abstract read
In one paragraph

Article in Journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shunsaku SogabeDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Hiroko NakanoDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Yusuke OgasaharaDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Pei-Chieng ChaDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Yuko AndoDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Mariko Taniguchi-IkedaDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Ryusaku MatsumotoDivision of Stem Cell Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Motoi KanagawaDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.ORCID http://orcid.org/0000-0003-0984-6398
Kazuhiro KobayashiDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.ORCID http://orcid.org/0000-0001-7801-147X
Shigeo MurayamaDepartment of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Tokyo, 173-0015, Japan.
Takashi AoiDivision of Stem Cell Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
Tatsushi TodaDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan. toda@m.u-tokyo.ac.jp.
Wataru SatakeDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan. satake@m.u-tokyo.ac.jp.

Funding

Japan Agency for Medical Research and Development (AMED) JP21wm0425019MEXT | Japan Society for the Promotion of Science (JSPS) JP22H04923MEXT | Japan Society for the Promotion of Science (JSPS) JP22K19487MEXT | Japan Society for the Promotion of Science (JSPS) JP23K21409
6 · The paper itself

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuron loss and α-synuclein aggregation. While some familial cases result from single-gene mutations, most are sporadic, involving complex genetic and environmental interactions. Among PD risk loci identified through genome-wide association studies, MCCC1 encodes a mitochondrial enzyme essential for leucine catabolism; however, the causal variant remains unclear. Here, we investigated whether the intronic variant rs12637471 regulates MCCC1 mRNA expression and influences PD risk. Postmortem brain analysis revealed significantly elevated MCCC1 mRNA levels in G-allele carriers, consistent with peripheral tissue eQTL data from GTEx. Using CRISPR/Cas9-edited induced pluripotent stem cells, we generated isogenic lines differing only at rs12637471 and observed increased MCCC1 expression in G-allele dopaminergic neurons. Given MCCC1's mitochondrial role, its dysregulation may impact mitochondrial homeostasis, autophagy, or inflammation, potentially contributing to PD pathogenesis.

Indexed as

IntronsParkinson DiseaseAllelesBrainCRISPR-Cas SystemsDopaminergic NeuronsFemaleGene Expression RegulationGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansInduced Pluripotent Stem CellsMaleMitochondriaPolymorphism, Single NucleotideQuantitative Trait LociRNA, Messenger

Identifiers

PMID40216992
PMCPMC12137145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.